Literature DB >> 15299068

Comparative 18F-FDG PET of experimental Staphylococcus aureus osteomyelitis and normal bone healing.

Jyri K Koort1, Tatu J Mäkinen, Juhani Knuuti, Jari Jalava, Hannu T Aro.   

Abstract

UNLABELLED: PET using (18)F-FDG is a promising imaging modality for bone infections, based on intensive consumption of glucose by mononuclear cells and granulocytes. The method may have limitations in distinguishing uncomplicated bone healing from osteomyelitis. Bone healing involves an inflammatory phase that represents a highly activated state of cell metabolism and glucose consumption, mimicking infection on PET images. This laboratory study of a standardized model was designed to compare the (18)F-FDG PET characteristics of normal bone healing with those of local osteomyelitis.
METHODS: A localized osteomyelitis model of the rabbit tibia was created by modifying a previously reported canine model. In the osteomyelitic group (n = 8), a standardized metaphyseal defect of the proximal right tibia was surgically created and filled with a block of orthopedic bone cement, followed by injection of a predetermined amount (0.1 mL) of Staphylococcus aureus (strain 52/52A/80, 1 x 10(5)/mL) into the space around the cement. The control group of animals with normal bone healing (n = 8) underwent the same procedure, but the bacterial injection was replaced by a sterile saline injection. The bone cement was surgically removed during debridement at 2 wk. Osteomyelitis was confirmed with positive bacterial cultures during the debridement and 6 wk later at the time of sacrifice. (18)F-FDG PET and peripheral quantitative CT were performed 3 and 6 wk after the debridement. The presence of osteomyelitic bone changes on plain radiographs was classified according to a previously published system.
RESULTS: Before surgery, the standardized uptake values of (18)F-FDG did not differ markedly between the right and left tibias. In the control animals, uncomplicated bone healing was associated with a temporary increase in (18)F-FDG uptake at 3 wk (P = 0.007), but it returned almost to normal by 6 wk. In the experimental animals, localized osteomyelitis resulted in an intense continuous uptake of (18)F-FDG, which was higher than that of healing and intact bones at 3 wk (P = 0.014 and P < 0.001, respectively) and at 6 wk (P < 0.001).
CONCLUSION: (18)F-FDG PET seems to be an efficient tool in the differentiation of uneventful bone healing from bone healing complicated by localized osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15299068

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  20 in total

1.  In vivo monitoring of Staphylococcus aureus biofilm infections and antimicrobial therapy by [18F]fluoro-deoxyglucose-MicroPET in a mouse model.

Authors:  Victoria Garrido; María Collantes; Montserrat Barberán; Iván Peñuelas; Javier Arbizu; Beatriz Amorena; María-Jesús Grilló
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  (68)Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones.

Authors:  Petteri Lankinen; Tatu J Mäkinen; Tiina A Pöyhönen; Pauliina Virsu; Satu Salomäki; Antti J Hakanen; Sirpa Jalkanen; Hannu T Aro; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-24       Impact factor: 9.236

3.  Nano-composite scaffolds for bone tissue engineering containing silver nanoparticles: preparation, characterization and biological properties.

Authors:  Eleonora Marsich; Francesca Bellomo; Gianluca Turco; Andrea Travan; Ivan Donati; Sergio Paoletti
Journal:  J Mater Sci Mater Med       Date:  2013-04-04       Impact factor: 3.896

4.  Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus.

Authors:  Tatu J Mäkinen; Petteri Lankinen; Tiina Pöyhönen; Jari Jalava; Hannu T Aro; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-09       Impact factor: 9.236

5.  Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.

Authors:  Jyri K Koort; Tatu J Mäkinen; Esa Suokas; Minna Veiranto; Jari Jalava; Juhani Knuuti; Pertti Törmälä; Hannu T Aro
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 6.  Biomaterials approaches to treating implant-associated osteomyelitis.

Authors:  Jason A Inzana; Edward M Schwarz; Stephen L Kates; Hani A Awad
Journal:  Biomaterials       Date:  2015-12-18       Impact factor: 12.479

7.  Animal models for the study of osteomyelitis.

Authors:  Mitul Patel; Yuri Rojavin; Amir A Jamali; Samantha J Wasielewski; Christopher J Salgado
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

Review 8.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT.

Authors:  Caixia Cheng; Christian Heiss; Antonia Dimitrakopoulou-Strauss; P Govindarajan; G Schlewitz; Leyun Pan; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

10.  Evaluation of new bone formation in normal and osteoporotic rats with a 3-mm femur defect: functional assessment with dynamic PET-CT (dPET-CT) using 2-deoxy-2-[(18)F]fluoro-D-glucose ( (18)F-FDG) and (18)F-fluoride.

Authors:  Caixia Cheng; Volker Alt; Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ulrich Thormann; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.